Aims and Scope of Current Cancer Drug Targets
Current Cancer Drug Targets is a peer-reviewed medical journal published by Bentham Science Publishers. The editor-in-chief is Ruiwen Zhang (UH Drug Discovery Institute). The journal covers research on contemporary molecular drug targets involved in cancer, including medicinal chemistry, pharmacology, molecular biology, genomics, and biochemistry. Current Cancer Drug Targets publishes original research reports, review papers, and rapid communications ("letters"). Less
Key Metrics
CiteScore 

6.4
H-Index 

99
Impact Factor 

< 5
SJR 

Q2Oncology

SNIP 

0.85
Recommended pre-submission checks
Powered by 

Topics Covered on Current Cancer Drug Targets
Current Cancer Drug Targets Journal Specifications
| Overview | |
| Publisher | BENTHAM SCIENCE PUBL LTD |
| Language | English |
| Frequency | Monthly |
| General Details | |
| Language | English |
| Frequency | Monthly |
| Publication Start Year | 2000 |
| Publisher URL | Visit website |
| Website URL | Visit website |
View less
Planning to publish in Current Cancer Drug Targets ?
Upload your Manuscript to get
- Degree of match
- Common matching concepts
- Additional journal recommendations

Recently Published Papers in Current Cancer Drug Targets
Hirsutanonol Inhibits the Progression of Hepatocellular Carcinoma by Promoting the Expression of CNDP1.
- 27 Jul 2026
- Current cancer drug targets
Targeting Oncogenic HER2 Mutations by Neratinib-induced HER2 Ubiquitination and Degradation in Breast Cancer.
- 24 Jul 2026
- Current cancer drug targets
Advances in Pharmacological Therapy for Recurrent High-Grade Meningiomas.
- 24 Jul 2026
- Current cancer drug targets
Targeting Ferroptosis in Adenocarcinoma of the Esophagogastric Junction: From a Natural Compound to Clinical Translation.
- 23 Jul 2026
- Current cancer drug targets
Overcoming Drug Resistance in Breast Cancer: Advances in Targeted and Combination Therapies.
- 22 Jul 2026
- Current cancer drug targets
LncRNA ABCA9-AS1 as a ceRNA Promotes Gastric Cancer Progression by Sponging miR-497-5p to Regulate KIF23 Expression.
- 22 Jul 2026
- Current cancer drug targets
Hirsutanonol Inhibits the Progression of Hepatocellular Carcinoma by Promoting the Expression of CNDP1.
- 27 Jul 2026
- Current cancer drug targets
Targeting Oncogenic HER2 Mutations by Neratinib-induced HER2 Ubiquitination and Degradation in Breast Cancer.
- 24 Jul 2026
- Current cancer drug targets
Advances in Pharmacological Therapy for Recurrent High-Grade Meningiomas.
- 24 Jul 2026
- Current cancer drug targets
Targeting Ferroptosis in Adenocarcinoma of the Esophagogastric Junction: From a Natural Compound to Clinical Translation.
- 23 Jul 2026
- Current cancer drug targets
Overcoming Drug Resistance in Breast Cancer: Advances in Targeted and Combination Therapies.
- 22 Jul 2026
- Current cancer drug targets
LncRNA ABCA9-AS1 as a ceRNA Promotes Gastric Cancer Progression by Sponging miR-497-5p to Regulate KIF23 Expression.
- 22 Jul 2026
- Current cancer drug targets
FAQs on Current Cancer Drug Targets
How long has Current Cancer Drug Targets been actively publishing? 
What is the publishing frequency of Current Cancer Drug Targets? 
How many articles did Current Cancer Drug Targets publish last year? 
What is the eISSN & pISSN for Current Cancer Drug Targets? 
What is Citescore for Current Cancer Drug Targets? 
What is the H Index for Current Cancer Drug Targets ? 
What is SNIP score for Current Cancer Drug Targets? 
What is the SJR for Current Cancer Drug Targets? 
Who is the publisher of Current Cancer Drug Targets? 
Check if your manuscript is a good match for
undefined
Upload your manuscript to get recommendations of journals
that have published papers similar to your manuscript
Drag and drop your file here
We accept manuscripts in English. File format: .doc and .docx | Maximum size: 10 MB | Word count: 200-300,000 words | File length: less than 100 pages
Do not have a manuscript right now? Use an abstract or summary